FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer
- On 19 October 2026 the FDA granted accelerated approval to Jemperli (dostarlimab) for stage II/III locally advanced rectal cancer.
- The dostarlimab approval covers tumours that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
- In the AZUR-1 trial of 154 patients, 71% were treated with dostarlimab alone, with no surgery or other therapy and no progression.
- The 12-month sustained clinical complete response with dostarlimab was 47% by independent review.
The US Food and Drug Administration granted accelerated approval on 19 October 2026 to GSK's Jemperli (dostarlimab) for adults with stage II/III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test.
The trial
Approval rests on AZUR-1, a single-arm trial of 154 previously untreated patients who received dostarlimab 500 mg intravenously every 3 weeks for nine cycles. Patients with a clinical complete response entered non-operative management with close, regular monitoring.
Also read: FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer
Results
Of the 154 patients, 110 (71%) were treated with dostarlimab alone, received no other treatment and had no disease progression; 26 (17%) had surgery. The 12-month sustained clinical complete response rate was 47% by independent central review among 116 evaluable patients and 68% by investigators, and the objective response rate was 79%. With a median follow-up of 26.3 months, no patient with a complete or near-complete response had progressed.
Limits
This is an accelerated approval, so continued approval depends on confirmatory trials, and AZUR-1 had no comparison group. The label includes warnings for immune-mediated and infusion-related reactions.
Sources: US Food and Drug Administration (FDA), CancerNetwork, Healio
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is new in the FDA approval of dostarlimab?
On 19 October 2026 the FDA granted accelerated approval to dostarlimab (Jemperli) for stage II/III locally advanced rectal cancer that is MSI-H or dMMR.
How is dostarlimab given for rectal cancer?
Dostarlimab is given as 500 mg intravenously every 3 weeks for nine cycles, unless there is unacceptable toxicity or disease progression.
How many patients avoided surgery with dostarlimab?
In AZUR-1, 110 of 154 patients (71%) were treated with dostarlimab alone, with no surgery or other treatment and no disease progression.
What was the sustained complete response rate with dostarlimab?
The 12-month sustained clinical complete response with dostarlimab was 47% by independent review and 68% by investigators in AZUR-1.
Why is the dostarlimab rectal cancer approval accelerated?
The dostarlimab approval is based on a single-arm trial, so continued approval depends on confirming clinical benefit in later studies.



